Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Delcath Systems, Inc. DCTH
$5.87
-$0.17 (-2.98%)
На 18:02, 12 мая 2023
+240.72%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
62102656.00000000
-
week52high
6.27
-
week52low
2.34
-
Revenue
2719000
-
P/E TTM
-1
-
Beta
0.85813100
-
EPS
-4.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 мая 2023 г. в 12:30
Описание компании
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 10 авг 2022 г. |
| BTIG | Buy | Buy | 24 июн 2022 г. |
| HC Wainwright & Co. | Buy | 10 дек 2021 г. | |
| Roth Capital | Buy | Buy | 06 апр 2021 г. |
| Canaccord Genuity | Buy | 09 мар 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | A | 459315 | 15215 | 14 дек 2022 г. |
| SALAMON STEVEN A J | A | 455315 | 15215 | 14 дек 2022 г. |
| Aharon Gil | A | 1258793 | 692042 | 13 дек 2022 г. |
| Rosalind Advisors, Inc. | A | 1258793 | 692042 | 13 дек 2022 г. |
| SALAMON STEVEN A J | A | 1258793 | 692042 | 13 дек 2022 г. |
| MICHEL GERARD J | A | 177589 | 51725 | 13 дек 2022 г. |
| MICHEL GERARD J | A | 125864 | 62814 | 20 июл 2022 г. |
| Aharon Gil | A | 566751 | 566751 | 18 июл 2022 г. |
| SALAMON STEVEN A J | A | 566751 | 566751 | 18 июл 2022 г. |
| Purpura John | A | 27021 | 3300 | 16 мая 2022 г. |
Новостная лента
Delcath Systems, Inc. (DCTH) Q3 2022 Earnings Call Transcript
Seeking Alpha
08 ноя 2022 г. в 13:33
Start Time: 08:30 January 1, 0000 9:00 AM ET Delcath Systems, Inc. (NASDAQ:DCTH ) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Gerard Michel - CEO Anthony Dias - VP of Finance Johnny John - VP, Clinical Development & Medical Affairs Kevin Muir - VP, Commercial Operations David Hoffman - General Counsel, Corporate Secretary and Chief Compliance Officer Conference Call Participants Sam Eiber - BTIG Scott Henry - ROTH Capital Yale Jen - Laidlaw & Company Bill Maughan - Canaccord Genuity Operator Good day, and welcome to the Delcath Systems Third Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.
Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022
PRNewsWire
01 сент 2022 г. в 16:15
NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C.
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
08 авг 2022 г. в 14:56
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants David Hoffman - General Counsel Gerard Michel - Chief Executive Officer Anthony Dias - Vice President of Finance Johnny John - Senior Vice President of Medical Affairs and Clinical Development Kevin Muir - Vice President of Commercial Operations John Purpura - Chief Operating Officer Conference Call Participants Scott Henry - Roth Capital Marie Sebalt - BTIG Bill Maughan - Canaccord Genuity Yale Jen - Laidlaw & Co Swayampakula Ramakanth - HC Wainright Operator Good morning, and welcome to the Delcath Systems Second Quarter Fiscal 2022 Financial Results Conference Call. All participants' will be in listen-only mode.
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
08 авг 2022 г. в 10:33
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -34.09% and 36.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems to Host Second Quarter 2022 Results
PRNewsWire
27 июл 2022 г. в 16:30
NEW YORK , July 27, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 8, 2022, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2022. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.